Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma - PubMed (original) (raw)

. 2012 Dec;29(5):3083-91.

doi: 10.1007/s12032-012-0305-x. Epub 2012 Aug 19.

Affiliations

Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma

Anchalee Techasen et al. Med Oncol. 2012 Dec.

Abstract

Epithelial-mesenchymal transition (EMT) is a series of events during which epithelial cells lose many of their epithelial characteristics and take on properties that are typical of mesenchymal cells that lack cell-cell adhesion properties. EMT may be activated by various types of growth factors or inflammatory cytokines. In many types of epithelial cancers, the EMT-derived tumor cells are susceptible to metastasis. During tumor progression, epithelial cells acquire a gene expression pattern closely resembling that of mesenchymal cells. This study aimed to investigate the expression of the EMT-associated transcription factor Snail and an adhesion molecule E-cadherin in cholangiocarcinoma (CCA) tissues. The effect of TNF-α on EMT activation in CCA cells was also demonstrated. The qRT-PCR analysis revealed that Snail expression significantly increased in CCA (P = 0.01) and was correlated with tumor metastasis (P = 0.02). The expression of Snail was inversely associated with E-cadherin (P = 0.004). The stimulation of TNF-α enhances migration behavior and showed significantly induced expression of Snail in CCA cell lines, whereas expression of E-cadherin and CK-19 (the epithelial marker) was reduced. Immunofluorescence analysis revealed that TNF-α-treated CCA cell lines increased nuclear translocation of Snail, whereas E-cadherin was dramatically decreased. Our findings suggest that the changes in the expression of Snail or E-cadherin might regulate EMT development in CCA resulting in promoting tumor progression. Overexpression of Snail could be used as a prognostic marker for monitoring the treatment efficiency of CCA patients.

PubMed Disclaimer

References

    1. Am J Pathol. 2010 Jul;177(1):141-52 - PubMed
    1. PLoS Med. 2007 Jul;4(7):e201 - PubMed
    1. Cancer Res. 2005 Jun 15;65(12):5153-62 - PubMed
    1. Cancer Sci. 2008 May;99(5):905-13 - PubMed
    1. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources